StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.67+0.15 (+9.87%)

Close on Nov 18, 2026Market cap $102.90MP/E –Yield –

Voyager Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Voyager Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $34.46M, down 19.1% year over year. For fiscal 2025 it was $40.37M, down 49.5% from the year before. Over ten years it grew 8.8% a year on average. The highest annual figure on record is $250.01M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$40.37M-49.5%
FY2024Dec 31, 2024$80.00M-68.0%
FY2023Dec 31, 2023$250.01M+511.2%
FY2022Dec 31, 2022$40.91M+9.3%
FY2021Dec 31, 2021$37.42M-78.1%
FY2020Dec 31, 2020$171.13M+63.9%
FY2019Dec 31, 2019$104.39M+1270.1%
FY2018Dec 31, 2018$7.62M-24.8%
FY2017Dec 31, 2017$10.14M-28.7%
FY2016Dec 31, 2016$14.22M-18.0%
FY2015Dec 31, 2015$17.33M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.17M-39.1%
Q1 FY2026Mar 31, 2026$2.59M-59.9%
Q4 FY2025Dec 31, 2025$15.34M+144.3%
Q3 FY2025Sep 30, 2025$13.37M-45.7%
Q2 FY2025Jun 30, 2025$5.20M-82.4%
Q1 FY2025Mar 31, 2025$6.47M-66.8%
Q4 FY2024Dec 31, 2024$6.28M-93.0%
Q3 FY2024Sep 30, 2024$24.63M+433.8%
Q2 FY2024Jun 30, 2024$29.58M+509.5%
Q1 FY2024Mar 31, 2024$19.52M-87.0%
Q4 FY2023Dec 31, 2023$90.06M+119.2%
Q3 FY2023Sep 30, 2023$4.61M+548.0%
Q2 FY2023Jun 30, 2023$4.85M+637.5%
Q1 FY2023Mar 31, 2023$150.48M+436.0%
Q3 FY2022Sep 30, 2022$41.09M+2672.3%
Q2 FY2022Jun 30, 2022$712.00K-47.5%
Q1 FY2022Mar 31, 2022$658.00K-89.9%
Q4 FY2021Dec 31, 2021$28.07M+329.4%
Q3 FY2021Sep 30, 2021$1.48M-98.7%
Q2 FY2021Jun 30, 2021$1.36M-95.3%
Q1 FY2021Mar 31, 2021$6.50M-64.0%
Q4 FY2020Dec 31, 2020$6.54M-80.0%
Q3 FY2020Sep 30, 2020$117.84M+476.7%
Q2 FY2020Jun 30, 2020$28.68M-37.8%
Q1 FY2020Mar 31, 2020$18.07M+247.6%
Q4 FY2019Dec 31, 2019$32.67M+1527.2%
Q3 FY2019Sep 30, 2019$20.43M+875.8%
Q2 FY2019Jun 30, 2019$46.09M+1689.8%
Q1 FY2019Mar 31, 2019$5.20M+451.7%
Q4 FY2018Dec 31, 2018$2.01M-68.4%
Q3 FY2018Sep 30, 2018$2.09M+82.4%
Q2 FY2018Jun 30, 2018$2.58M+118.8%
Q1 FY2018Mar 31, 2018$942.00K-35.7%
Q4 FY2017Dec 31, 2017$6.35M+168.7%
Q3 FY2017Sep 30, 2017$1.15M-65.3%
Q2 FY2017Jun 30, 2017$1.18M–
Q1 FY2017Mar 31, 2017$1.46M–
Q4 FY2016Dec 31, 2016$2.36M–
Q3 FY2016Sep 30, 2016$3.31M–

More Voyager Therapeutics figures

See a number that looks wrong?